Cspc Zhongnuo Pharmaceutical (shijiazhuang) Co., Ltd.
Clinical trials sponsored by Cspc Zhongnuo Pharmaceutical (shijiazhuang) Co., Ltd., explained in plain language.
Pharmaceutical manufacturer, subsidiary of CSPC Group.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New injection aims to tackle hidden heart risk
Disease control Not yet recruitingThis Phase 2 trial tests an experimental injection called SYH2068 in 120 adults with high lipoprotein(a), a genetic risk factor for heart disease. Participants receive either the drug or a placebo to see if it safely lowers their Lp(a) levels over several months. The goal is to f…
Phase: PHASE2 • Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New hope for stubborn high blood pressure? phase 3 trial launches
Disease control Not yet recruitingThis Phase 3 trial tests aprocitentan, a drug already approved in some countries, for people with resistant hypertension—high blood pressure that stays high despite taking three or more medications. About 382 adults will receive either the drug or a placebo for 8 weeks. The main …
Phase: PHASE3 • Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New schizophrenia shot could offer cheaper alternative to abilify maintena
Disease control Not yet recruitingThis study compares a new injectable form of aripiprazole (SYH9096) to the approved drug Abilify Maintena® in 116 adults with stable schizophrenia. Participants receive five injections of each version, one month apart, to see if the new version reaches similar drug levels in the …
Phase: NA • Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New shot could help lower stubborn high cholesterol
Disease control Not yet recruitingThis Phase 3 trial tests an injection called SYH2053 for people with high cholesterol that isn't controlled by standard pills. About 900 adults aged 18-75 will receive either the drug or a placebo, on top of their usual cholesterol medication. The main goal is to see if SYH2053 s…
Phase: PHASE3 • Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC